Jacob A. Frenkel - 24 Jul 2026 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Director
Issuer ticker: BCLI
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 17:01:57 UTC
Prior SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacob A. Frenkel

Key filing fact

Jacob A. Frenkel filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 28 Jul 2026.

Key facts

This page summarizes Jacob A. Frenkel's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jul 2026, 17:01.

Change

Previous filing in this sequence was filed on 29 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001237418 Primary reporting owner

FRENKEL JACOB A

Relationship: Director
Address: C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FLOOR, NEW YORK
Signature: /s/ Jacob A. Frenkel
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value
Shares: +100,000
Change %: +41%
Price: $0.000000^*
Shares after: 343,777
Date: 24 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jacob A. Frenkel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents shares of restricted stock units ("RSUs") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the "Consulting Agreement") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date.